Antiviral therapy for chronic hepatitis C: is there a time to change existing standards?
Abstract
The aim of review. To analyze efficacy of antiviral therapy of various duration in patients with chronic hepatitis C (CHC).
Original positions of the report. According to published data viremia dynamics has important prognostic value during treatment, which allows to consider it as one of important factors determining duration and efficacy of treatment along with virus genotype. Poor efficacy of the latter, especially at patients with the 1-st HCV genotype, high cost and risk of the serious undesirable effects cause necessity to individualize antiviral therapy at CHC, improve risk/benefit ratio.
Conclusion. At CHC patients with the rapid virologic response (absence of viremia at the 4-th week) it is possible to limit duration of treatment by pegilated interferon and ribavirin in the case of the 1-st HCV genotype to 24 wks, in the case of the 2 and 3-rd genotypes to 12–16 wk. In patients with the 3-rd HCV genotype without rapid virologic response and in patients with the 1-st HCV genotype and slow virologic response treatment probably should be prolonged to 48 and 72 wks respectively.
About the Author
D. T. Abdurakhmanov
Московская медицинская академия им. И.М. Сеченова
Russian Federation
Russian Federation
References
1. Andriulli A., Cursaro C., Cozzolongo R. et al. Early discontinuation of ribavirin in HCV-2 and HCV-3 patients responding to peg-interferon alfa-2a and ribavirin. Program and abstracts of the 58th Annual Meeting of the American Association for the Study of Liver Diseases, November 2–6, 2007, Boston: Abstract 234.
2. Berg T., von Wagner M., Nasser S. et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin // Gastroenterology. – 2006. – Vol. 130. – P. 1086–1097.
3. Berg T., Weich V., Teuber G. et al. Individualized treatment strategy with peginterferon alpha-2b plus ribavirin according to early viral kinetics in hepatitis C virus (HCV) type 1 infected patients // J. Hepatol. – 2006. – Vol. 44 (suppl. 2). – P. 208.
4. Dalgard O., Bjoro K., Ring-Larsen H., Verbaan H. Peginterferon alfa-2b and ribavirin for 14 or 24 weeks in patients with HCV genotype 2 or 3 and rapid virological response. North-C trial // J. Hepatol. – 2006. – Vol. 46. – P. 1–57.
5. Ferenci P., Bergholz U., Laferl H. et al. 24 week treatment regimen with peginterferon alpha-2a (40KD) (Pegasys) plus ribavirin (Copegus) in HCV genotype 1 or 4 «super-responders» // J. Hepatol. – 2006. – Vol. 44 (suppl. 2). – P. 5.
6. Ferenci P., Fried M., Shiffman M. et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin // J. Hepatol. – 2005. – Vol. 43. – P. 425–433.
7. Ferenci P., Laferi H., Scherzer T. et al. Customizing treatment with peginterferon alfa-2a plus ribavirin in patients with HCV genotype 1 or 4 infection: interim results of a prospective randomized trial. Program and abstracts of the 57th Annual Meeting of the American Association for the Study of Liver Diseases, October 27–31, 2006, Boston, Massachusetts: Abstract 390.
8. Fried M.W., Shiffman M.L., Reddy K.R. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection // N. Engl. J. Med. – 2002. – Vol. 347. – P. 975–982.
9. Galeras J.A., Gimenez M.D., Marquez C. et al. Predictive value and predictive factors of the rapid virological response in chronic hepatitis C treatment // J. Hepatol. – 2006. – Vol. 44. – P. 2–212.
10. Hadziyannis S.J., Sette H.J., Morgan T.R. et al. Peginterferon-alfa 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose // Ann. Intern. Med. – 2004. – Vol. 140. – P. 346–355.
11. Jensen D., Morgan T., Marcellin P. et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy // Hepatology. – 2006. – Vol. 43. – P. 954–960.
12. Mangia A., Minerva N., Bacca D. et al. In pts who clear HCVRNA at week 12, SVR is higher after 72 than after 48 weeks tx: results of a randomized controlled trial (RCT). Program and abstracts of the 42nd Annual Meeting of the EASL, April 11–15, 2007, Barcelona, Spain: Abstract 7.
13. Mangia A., Santoro R., Minerva N. et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3 // N. Engl. J. Med. – 2005. – Vol. 352. – P. 2609–2617.
14. Manns M.P., McHutchison J.G., Gordon S.C. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial // Lancet. – 2001. – Vol. 358. – P. 958–965.
15. Pearlman B., Ehleben C., Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders // Hepatology. – 2007. – Vol. 46. – P. 1688–1694.
16. Sбnchez-Tapias J.M., Diago M., Escartнn P. et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment // Gastroenterology. – 2006. – Vol. 131. – P. 451–460.
17. Shiffman M.L., Pappas S., Nyberg L. et al. Peginterferon alpha-2a (Pegasys) plus ribavirin (Copegus) for 16 or 24 weeks in patients with HCV genotype 2 or 3. Final results of the accelerate trial // J. Hepatol. – 2006. – Vol. 44. – P. 2–270.
18. Soriano V., Puoti M., Sulkowski M. et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV–HIV International Panel // AIDS. – 2007. – Vol. 21. – P. 1073–1089.
19. Von Wagner M., Huber M., Berg T. et al. Peginterferon-alfa-2a and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C // Gastroenterology. – 2005. – Vol. 129, N 2. – P. 522–527.
20. Willems B., Hadziyannis S.J., Morgan T.R. et al. Should treatment with peginterferon plus ribavirin be intensified in patients with HCV genotype 2/3 without a rapid virological response? // J. Hepatol. – 2006. – Vol. 46. – P. 1–6.
21. Zeuzem S., Buti M., Ferenci P. et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia // J. Hepatol. – 2006. – Vol. 44. – P. 97–103.
Review
For citations:
Abdurakhmanov D.T. Antiviral therapy for chronic hepatitis C: is there a time to change existing standards? Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2009;19(1):16-21. (In Russ.)
Views:
50
Email this article 
